LH · Categories · M&A
LH - Mergers and acquisitions
Labcorp Holdings Inc. (LH) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for LH
- Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 GuidanceResults from Operations for first quarter 2026 versus first quarter 2025:Revenue: $3.54 billion vs. $3.35 billion, up 5.8%Diluted EPS: $3.35 vs. $2.52, up 32.8%Adjusted EPS: $4.25 vs. $3.84, up 10.6%Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpointAdjusted EPS range of $17.70 to $18.35; up 13 cents at the midpointAdvanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborationsCollaborated with Optum.ai to enhance patient and provider experienceBURLINGTON, N.C., April 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (NYSE:LH), a global leader of innovative and comprehen
- NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of LabcorpTOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear
- Dynacare Acquires Valley Medical LaboratoriesBrampton, Ont., April 19, 2023 (GLOBE NEWSWIRE) -- Dynacare, a Labcorp subsidiary and one of Canada's leading health and wellness solutions providers, today announced that they have entered into an agreement to acquire Valley Medical Laboratories in British Columbia effective May 1, 2023. The combined strength of Dynacare and Valley Medical will offer an expansive patient service centre network and diagnostic test menu to patients, customers, and the healthcare community. Under the agreement, Dynacare will continue to provide superior laboratory services including collection and testing across Valley Medical's network of 14 locations in the Okanagan Valley (Osoyoos, Penticton, Peachland
- Labcorp Acquires Clinical Outreach Laboratory Services From RWJBarnabas HealthTransaction Expands Labcorp's Footprint with New Jersey's leading academic health system Labcorp (NYSE:LH), a leading global life sciences company, today announced that it has closed its acquisition of RWJBarnabas Health's outreach laboratory business and select related assets. RWJBarnabas Health is New Jersey's largest academic health system. "The communities, physicians and health systems we serve are central to everything we do at Labcorp," said Bill Haas, senior vice president of Labcorp Diagnostic's Northeast Division. "Our expanded relationship with RWJBH will build on the solid foundation RWJBarnabas Health has developed, and will offer patients and providers enhanced access to hig
- Labcorp Acquires Diagnostic Clinical Laboratory Services From AtlantiCareArrangement Expands Labcorp's Services to Patients and Providers in Southern New Jersey Labcorp (NYSE:LH), a leading global life sciences company, and AtlantiCare, the largest health care organization in southern New Jersey, today announced that they have closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare's clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey. The transaction is the latest in a series of new and expanded collaborations between Labcorp and health systems across the country, demonstrating the value that Labcorp br
- Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation InitiativesHighlights: Revenue of $173.1 million increases 12% sequentiallyGAAP earnings per share of ($0.52), adjusted EPS of ($0.06) improves $0.06 sequentiallyTotal test volumes increase 5% sequentially despite typical seasonality, with average revenue per test also increasing relative to the Dec. quarterExpect to close on the sale of the three planned business unit divestitures by the end of 3Q21 for total gross proceeds of approximately $375 millionCompany to host Investor Day on May 4th at 11 am EDT Paul J. Diaz, President and Chief Executive Officer:"Myriad Genetics returned to year-over-year top line growth in the March quarter through improved operational execution amidst the challen